ArticleHuman molecular genetics2011
Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice.
Article in Human molecular genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Advances and Therapeutic Potential of Anthraquinone Compounds in Neurodegenerative Diseases: A Comprehensive Review.Drug design, development and therapy · 2026Review
- Update on the Symptomatic Treatment of Huntington's Disease: From Pathophysiology to Clinical Practice.International journal of molecular sciences · 2025Review
- Luteolin as potential treatment for Huntington's disease: Insights from a transgenic mouse model.CNS neuroscience & therapeutics · 2024Article
- Brain-Derived Neurotrophic Factor - The Protective Agent Against Neurological Disorders.CNS & neurological disorders drug targets · 2024Article
- Efficacy of Electroconvulsive Therapy for the Treatment of Movement Disorders: A Literature Review.Cureus · 2023Review
- Brain-Derived Neurotropic Factor in Neurodegenerative Disorders.Biomedicines · 2022Review
- Electroconvulsive seizure inhibits the mTOR signaling pathway via AMPK in the rat frontal cortex.Psychopharmacology · 2022Article
- Electroconvulsive Therapy and Movement Disorders. New Perspectives on A Time-Tested Therapy.Movement disorders clinical practice · 2021Review
- Potential biomarkers of emotional stress induced neurodegeneration.eNeurologicalSci · 2020Review
- Electroconvulsive Seizures Induce Autophagy by Activating the AMPK Signaling Pathway in the Rat Frontal Cortex.The international journal of neuropsychopharmacology · 2020Article
- Brain-derived neurotrophic factor and its clinical implications.Archives of medical science : AMS · 2015Article
- BDNF mediates adaptive brain and body responses to energetic challenges.Trends in endocrinology and metabolism: TEM · 2014Review
- Modified electroconvulsive therapy for the treatment of refractory schizophrenia-like psychosis associated with Huntington's disease.Journal of neurology · 2013Article
- Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Molecular neurobiology · 2012Review
- Mouse models of polyglutamine diseases: review and data table. Part I.Molecular neurobiology · 2012Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Huntington's disease (HD) is an inherited neurodegenerative disorder caused by expanded polyglutamine repeats in the huntingtin (Htt) protein. Mutant Htt may damage and kill striatal neurons by a mechanism involving reduced production of brain-derived neurotrophic factor (BDNF) and increased oxidative and metabolic stress. Because electroconvulsive shock (ECS) can stimulate the production of BDNF and protect neurons against stress, we determined whether ECS treatment would modify the disease process and provide a therapeutic benefit in a mouse model of HD. ECS (50 mA for 0.2 s) or sham treatment was administered once weekly to male N171-82Q Htt mutant mice beginning at 2 months of age. Endpoints measured included motor function, striatal and cortical pathology, and levels of protein chaperones and BDNF. ECS treatment delayed the onset of motor symptoms and body weight loss and extended the survival of HD mice. Striatal neurodegeneration was attenuated and levels of protein chaperones (Hsp70 and Hsp40) and BDNF were elevated in striatal neurons of ECS-treated compared with sham-treated HD mice. Our findings demonstrate that ECS can increase the resistance of neurons to mutant Htt resulting in improved functional outcome and extended survival. The potential of ECS as an intervention in subjects that inherit the mutant Htt gene merits further consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.